License Agreements (Details) $ in Millions |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Dec. 08, 2022 |
Mar. 22, 2022
USD ($)
payment
|
Dec. 31, 2023
USD ($)
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Lonza milestone payment | Research and development | |||||
| License Agreements | |||||
| Annual milestone payment, due and payable | $ 0.4 | ||||
| Lonza milestone payment | Accounts Payable and Accrued Liabilities | |||||
| License Agreements | |||||
| Annual milestone payment, due and payable | $ 0.4 | $ 0.4 | |||
| Wuxi Biologics License | |||||
| License Agreements | |||||
| Amount of license costs payable | 0.0 | ||||
| Agreement with Pfizer | |||||
| License Agreements | |||||
| Development Of research and development | $ 1.0 | ||||
| Number of development and regulatory milestone payments | payment | 11 | ||||
| Maximum amount of development and regulatory milestone payments | $ 69.0 | ||||
| Maximum amount of sales milestone payments | $ 525.0 | ||||
| Maximum annual earned royalty at a marginal royalty rate | 20.00% | 20.00% | |||
| Amount of license costs payable | $ 0.0 |